PT  - JOURNAL ARTICLE
AU  - Mika Ala-Korpela
AU  - Siyu Zhao
AU  - Marjo-Riitta Järvelin
AU  - Ville-Petteri Mäkinen
AU  - Pauli Ohukainen
TI  - Apt interpretation of comprehensive lipoprotein data in large-scale epidemiology – disclosure of fundamental structural and metabolic relationships
AID  - 10.1101/2021.03.08.21253123
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.08.21253123
4099  - http://medrxiv.org/content/early/2021/03/08/2021.03.08.21253123.short
4100  - http://medrxiv.org/content/early/2021/03/08/2021.03.08.21253123.full
AB  - Aims Quantitative lipoprotein analytics by NMR spectroscopy is currently commonplace in large-scale studies. One methodology has become widespread and is currently being utilised also in large biobanks. It allows comprehensive characterisation of 14 lipoprotein subclasses, clinical lipids, apolipoprotein A-I and B. The details of these data are conceptualised here in relation to lipoprotein metabolism with particular attention to the fundamental characteristics of subclass particle numbers, lipid concentrations and compositional measures.Methods and Results The NMR methodology was applied to fasting serum samples from Northern Finland Birth Cohort 1966 and 1986 with 5,651 and 5,605 participants, respectively. All results were highly coherent between the cohorts. Circulating lipid concentrations in a particular lipoprotein subclass arise predominantly as the result of the circulating number of those subclass particles. The spherical lipoprotein particle shape, with a radially oriented surface monolayer, imposes size-dependent biophysical constraints for the lipid composition of individual subclass particles and inherently restricts the accommodation of metabolic changes via compositional modifications. The new finding that the relationship between lipoprotein subclass particle concentrations and the particle size is log-linear reveal that circulating lipoprotein particles are also under rather strict metabolic constraints for both their absolute and relative concentrations.Conclusion The fundamental structural and metabolic relationships between lipoprotein subclasses elucidated in this study empower detailed interpretation of lipoprotein metabolism. Understanding the intricate details of these extensive data is consequential for the precise interpretation of novel therapeutic opportunities and for fully utilising the potential of forthcoming analyses of genetic and metabolic data in extensive biobanks.One-sentence Summary NMR spectroscopy facilitates comprehensive characterisation of lipoprotein subclass metabolism and offers additional value to epidemiology, genetics and pharmacology in large-scale studies and biobanks.Key MessagesThe circulating particle number of a lipoprotein subclass is the defining measure for its lipid concentrations; the particle lipid composition is only in a minor role. The relationship between circulating lipoprotein subclass particle concentrations and the particle size is log-linear.The overall structure of lipoprotein subclass particles with a spherical shape and an oriented surface monolayer poses strong size-dependent biomolecular constraints for their lipid composition.The circulating lipoprotein subclass particle concentrations in humans are metabolically constraint for both elemental absolute and relative concentration ranges.The smallest HDL particle concentrations are negatively associated with those of large HDL and generally the associations of the smallest HDL particles are similar to those of apolipoprotein B-containing particles.The apolipoprotein B-containing particles constitute less than 10% of all lipoprotein particles but carry around two thirds of circulating lipoprotein lipids. LDL and IDL particles amount to almost 90% of all apolipoprotein B-containing particles.The supplemental role of lipoprotein subclass data in cardiometabolic risk assessment is slight.In the current era of biobanks and big data, the combination of lipoprotein subclass data with drug-target Mendelian randomization analyses provides great scientific synergy, intricate details and potential cost savings in drug development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMAK is supported by a research grant from the Sigrid Juselius Foundation, Finland. PO is supported by the Emil Aaltonen Foundation. The Northern Finland Birth Cohorts have received funding from the Academy of Finland, Novo Nordisk Foundation, and EU.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies comply with the Declaration of Helsinki, were approved by the local ethics committee (Northern Ostrobothnia Hospital District, Finland) and written informed consents were obtained from each participant.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used in the current study are available from the cohorts through application process for researchers who meet the criteria for access to confidential data: https://www.oulu.fi/nfbc/.